Phase I/II and pharmacokinetic study of cladribine with 2‐h infusion in Japanese patients with relapsed indolent B‐cell lymphoma mostly pretreated with rituximab
暂无分享,去创建一个
Y. Ohashi | Y. Matsuno | S. Nawano | M. Ogura | S. Mori | K. Tobinai | D. Maruyama | K. Itoh | Y. Morishima | Takashi Watanabe | T. Terauchi | M. Nakata | M. Kasai | M. Matsusako | K. Tanimoto | N. Usui | Shigeo Nakamura | S. Nakamura
[1] M. Gordon,et al. Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma , 2009 .
[2] R. Marcus,et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Czyż,et al. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low‐grade B‐cell non‐Hodgkin lymphoma patients , 2008, Cancer.
[4] Y. Ohashi,et al. Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R-CHOP) in untreated indolent B-NHL: 7-year follow-up results , 2008 .
[5] A. Saven,et al. Cladribine in indolent non-Hodgkin’s lymphoma , 2008, Expert review of anticancer therapy.
[6] K. Sułek,et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). , 2006, Blood.
[7] M. Taniwaki,et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[9] R. Fisher,et al. New treatment options have changed the survival of patients with follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Y. Ohashi,et al. Phase II Clinical Study of Cladribine in the Treatment of Hairy Cell Leukemia , 2005, International Journal of Hematology.
[11] T. Robak,et al. Activity of Cladribine Combined with Etoposide in Heavily Pretreated Patients with Indolent Lymphoid Malignancies , 2005, Chemotherapy.
[12] Y. Ohashi,et al. Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin’s Lymphomas: Results of a Japanese Phase II Study , 2004, International journal of hematology.
[13] P. Smolewski,et al. Rituximab Followed by Cladribine in the Treatment of Heavily Pretreated Patients with Indolent Lymphoid Malignancies , 2004, Leukemia & lymphoma.
[14] J. Armitage,et al. Treatment of Indolent Non-Hodgkin’s Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone , 2004, International journal of hematology.
[15] M. Matsuoka,et al. Phase II Study of Cladribine (2-Chlorodeoxyadenosine) in Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma , 2003, International journal of hematology.
[16] K. Tobinai. Rituximab and other emerging monoclonal antibody therapies for lymphoma , 2002, Expert opinion on emerging drugs.
[17] M. Hansmann,et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. , 2002, European journal of cancer.
[18] J. Molinuevo,et al. Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: Long‐term follow‐up of patients , 2002, Movement disorders : official journal of the Movement Disorder Society.
[19] A. Santoro,et al. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] M. Hansmann,et al. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. , 1999, Leukemia & lymphoma.
[22] J. Góra‐Tybor,et al. Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma. , 1999, Leukemia & lymphoma.
[23] B. Nathwani,et al. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non‐Hodgkin's lymphoma , 1998, Cancer.
[24] J. Koziol,et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. , 1998, Blood.
[25] A. Chott,et al. Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma. , 1998, European journal of cancer.
[26] Y. Ohashi,et al. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. , 1997, Japanese journal of clinical oncology.
[27] J. Zaucha,et al. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma. , 1997, Leukemia & lymphoma.
[28] G. Juliusson,et al. Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma. , 1997, Leukemia & lymphoma.
[29] A. Saven,et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Rademaker,et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Juliusson,et al. Cellular pharmacokinetics of 2-chloro-2'-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] L. Gordon,et al. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] G. Juliusson,et al. High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] E. Beutler. Cladribine (2-chlorodeoxyadenosine) , 1992, The Lancet.
[35] A. Saven,et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] D. Carson,et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. , 1990, The New England journal of medicine.
[37] A. Yu,et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes , 1983 .
[38] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.